Ticker | Company Name | Drug Name | Indication | NCT | Next Catalyst | Stage | FDA Status | Catalyst Date | Conference | Market Cap | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
L LNTH | Lantheus Holdings Inc. | PYLARIFY (piflufolastat F 18) Injection | Prostate Cancer | Regulatory Decision | PDUFA | Ongoing | 2026-03-06 | $5.2B | $1.5M | ||
B BMY | Bristol-Myers Squibb Company | Sotyktu (deucravacitinib) - (POETYK PsA-1) | Psoriatic Arthritis | NCT04908202 | PDUFA priority review | Data Released | 2026-03-06 | $124.7B | $14.0M | ||
G GSK | GSK plc American Depositary Shares (Each representing two) | Linerixibat - (GLISTEN) | Primary biliary cholangitis (PBC) | PDUFA | 2026-03-24 | $114.5B | $4.1M | ||||
R RCKT | Rocket Pharmaceuticals Inc. | KRESLADI (marnetegragene autotemcel) | Leukocyte Adhesion Deficiency-I (LAD-I) | NCT03812263 | Regulatory Decision | PDUFA | Ongoing | 2026-03-28 | $519.5M | $2.9M | |
R RXRX | Recursion Pharmaceuticals Inc. | REC-394 | C. difficile | Interim Data | Phase 2 | Ongoing | 2026-03-31 | $1.8B | $70.2M | ||
C CTMX | CytomX Therapeutics Inc. | EpCAM-directed ADC (CX-2051) | Solid Tumors | NCT06265688 | Interim Data | Phase 1 | Trial Planned | 2026-03-31 | $815.0M | $1.2M | |
B BTAI | BioXcel Therapeutics Inc. | BXCL501 - (SERENITY III) | Agitation associated with bipolar I or II disorder or schizophrenia | NCT05658510 | Topline Data | Phase 3 | Data Released | 2026-03-31 | $35.0M | $943.8K | |
A ACET | Adicet Bio Inc. | ADI-001 | Lupus nephritis and Systemic Lupus Erythematosus (SLE) | End of Phase Meeting | Phase 2 | Trial Planned | 2026-03-31 | $67.4M | $1.9M | ||
I IONS | Ionis Pharmaceuticals Inc. | Zilganersen (ION373) | Alexander disease | NCT04849741 | Submission | NDA Filing | Ongoing | 2026-03-31 | $12.7B | $1.3M | |
M MAZE | Maze Therapeutics Inc. | MZE829 | APOL1 kidney disease | Initial Data | Phase 2 | Trial Planned | 2026-03-31 | $2.1B | $195.0K |
Rows per page
Page 1 of 36